L. JARA PALOMARES (Sevilla, Spain), T. Pulido Zamudio (México D.F, Mexico)
Acute beat blockade improves right ventricular diastolic filling in pulmonary arterial hypertension: a rodent CMR and clinical human pressure-volume study
C. Samaranayake (London, United Kingdom), M. Niglas (London, United Kingdom), A. Kempny (London, United Kingdom), N. Baxan (London, United Kingdom), A. Ashek (London, United Kingdom), J. Pinguel (London, United Kingdom), K. Dimopoulos (London, United Kingdom), L. Price (London, United Kingdom), S. Wort (London, United Kingdom), L. Zhao (London, United Kingdom), C. Mccabe (London, United Kingdom)
|   |
Haemodynamic (HD) evaluation of LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH)
B. Egenlauf (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), S. Patel (Morrisville, United States), A. Galloway (Morrisville, United States), E. Grünig (Heidelberg, Germany)
| |
Combination therapy prescribing in pulmonary arterial hypertension patients in a real-world setting in Latin America
T. Pineda (Bogota, Colombia), A. Bennett (Bollington, United Kingdom), I. Bluro (Buenos Aires, Argentina), J. Harley (Bollington, United Kingdom), J. Irias (Panamá city, Panama), T. Pulido (Mexico City, Mexico), A. Ramirez (Nuevo León, Mexico), C. Rozo Bedoya (Bogota, Colombia), M. Small (Bollington, United Kingdom), M. Orozco-Levi (Santander, Colombia)
| |
Macitentan real-world experience in elderly patients over 75 years with pulmonary arterial hypertension (PAH)
N. Kim (La Jolla, United States), R. Channick (Los Angeles, United States), K. Chin (Dallas, United States), L. Mitchell (Allschwil, Switzerland), S. Turricchia (Allschwil, Switzerland), R. Ong (Allschwil, Switzerland), V. Mclaughlin (Ann Arbor, United States)
| |
CARE PAH study design: an international, prospective real-world cohort of PAH patients
M. Humbert (Paris, France), N. Dreyer (Cambridge, United States), V. Mclaughlin (Ann Arbor, United States), T. Pulido (Mexico City, Mexico), N. Boyanova (Allschwil, Switzerland), B. Frauchiger (Allschwil, Switzerland), F. Kiefer (Allschwil, Switzerland), C. Lassen (Allschwil, Switzerland), R. Ong (Allschwil, Switzerland), L. Sanna (Allschwil, Switzerland), A. Sauter (Allschwil, Switzerland), D. Kiely (Sheffield, United Kingdom)
| |
Tolerability,safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol(Veletri®):6-months,open label,observational,non-interventional study
J. Degering (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), R. Seeger (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)
| |
Retrospective on the Developing World's Participation in Pulmonary Hypertension Clinical Trials: 1999-2021
L. Zheng (Zheng zhou, China), S. Wang (Shanghai shanghaiSHANGHAI SHANGH Shanghai, China), Y. Yan (munishanghaiSHANGHAI SHANGH Shanghai, Germany), P. Yuan (Shanghai shanghaiSHANGHAI SHANGH Shanghai, China), R. Jiang (Shanghai shanghaiSHANGHAI SHANGH Shanghai, China)
| |
Mean Size of Atrial Shunt predicts Survival in Pulmonary Hypertension patients undergoing Atrial Septostomy
R. Zebadua (CDMX, Mexico), N. Zayas (CDMX, Mexico), J. Lopez (CCDMX, Mexico), M. Pozas (CCDMX, Mexico), L. Zorrila (CCDMX, Mexico), J. Sandoval (CCDMX, Mexico), T. Pulido (CCDMX, Mexico), N. Zayas Hdz. (La Paz, Mexico)
| |
Effect of breathing oxygen-enriched air on exercise performance in healthy and different cardiopulmonary diseasesData from 5 RCTs.
J. Müller (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), P. Appenzeller (Zürich, Switzerland), E. Hasler (Zürich, Switzerland), M. Furian (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Effect of acetazolamide on incremental cycling exercise in precapillary pulmonary hypertension. A randomized placebo-controlled, double blind, cross-over trial
J. Müller (Zürich, Switzerland), P. Appenzeller (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), M. Furian (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Efficacy of oral treprostinil as an add-on therapy for PAH
D. Kiely (Sheffield, United Kingdom), E. Grünig (Heidelberg, Germany), V. Balasubramanian (Fresno, United States), J. Barberà (Barcelona, Spain), C. Vizza (Rome, Italy), J. Elwing (Cincinnati, United States), N. Sood (Davis, United States), Y. Rao (Research Triangle Park, United States), L. Holdstock (Research Triangle Park, United States), S. Seaman (Research Triangle Park, United States), M. Broderick (Research Triangle Park, United States), R. White (Rochester, United States)
| |
Long-term clinical assessment in patients with Eisenmenger Syndrome treated with macitentan
R. Zebadua (Ciudad de México, Mexico), J. López (Ciudad de México, Mexico), N. Zayas (Ciudad de México, Mexico), J. Sandoval (Ciudad de México, Mexico), M. Villalobos-Pedroza (Ciudad de México, Mexico), A. Cruz (Ciudad de México, Mexico), D. Hernández (Ciudad de México, Mexico), J. Canul (Ciudad de México, Mexico), T. Pulido (Ciudad de México, Mexico), N. Zayas Hdz. (La Paz, Mexico)
| |
Feasibility, acceptability, safety and efficacy of a remotely delivered home-based pulmonary hypertension exercise program
C. McCormack (Dublin, Ireland), B. Kehoe (Waterford, Ireland), S. Cullivan (Dublin, Ireland), N. Mccaffrey (Dublin, Ireland), S. Gaine (Dublin, Ireland), B. Mccullagh (Dublin, Ireland), A. Mccarren (Dublin, Ireland), S. Hardcastle (Fremantle, Australia), N. Moyna (Dublin, Ireland)
| |
Survival of patients diagnosed with Pulmonary Hypertension undergoing Atrial Septostomy
R. Zebadua (CDMX, Mexico), N. Zayas (CDMX, Mexico), J. Lopez (CDMX, Mexico), L. Zorrilla (CDMX, Mexico), M. Pozas (CDMX, Mexico), M. Villalobos (CDMX, Mexico), J. Sandoval (CDMX, Mexico), T. Pulido (CDMX, Mexico), N. Zayas Hdz. (La Paz, Mexico)
| |
Predictors of the response to combined therapy with phosphodiesterase-5 inhibitors and endothelin receptor antagonists in pulmonary arterial hypertension
A. GARCIA (Barcelona, Spain), I. Blanco (Barcelona, Spain), M. Lopez Meseguer (Barcelona, Spain), J. Domingo Morera (Zaragoza, Spain), C. Martin Ontiyuelo (Barcelona, Spain), O. Tura Ceide (Barcelona, Spain), I. Otero Gonzalez (A Coruña, Spain), P. Escribano Subías (Madrid, Spain), J. Albert Barberà (Barcelona, Spain)
| |
Effects of Molsidomin upon pulmonary hemodynamics and oxygen transport by arterial blood in chronic obstructive pulmonary disease (COPD) and decompensated cor pulmonale
V. Calancea (Chisinau, Republic of Moldova), E. Terna (Chisinau, Republic of Moldova), C. Martiniuc (Chisinau, Republic of Moldova), S. Eremciuc (Chisinau, Republic of Moldova), I. Sirbu (Chisinau, Republic of Moldova), C. Matcovschi (Chisinau, Republic of Moldova), E. Calancea (Chisinau, Republic of Moldova), S. Matcovschi (Chisinau, Republic of Moldova)
| |
Cardiorespiratory adaptation whilst breathing normobaric hypoxia vs. short-term exposure to altitude in patients with pulmonary hypertension.
S. Schneider (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), M. Furian (Zürich, Switzerland), L. Mayer (Zürich, Switzerland), J. Müller (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Late Breaking Abstract - Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: a randomized, double-blind, cross-over trial
M. Lichtblau (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), J. Müller (Zürich, Switzerland), P. Appenzeller (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), L. Mayer (Zürich, Switzerland), M. Furian (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), E. Swenson (Seattle, United States), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Late Breaking Abstract - Cannabidiol reduces lung and heart fibrosis in rats with monocrotaline-induced pulmonary hypertension
A. Krzyzewska (Bialystok, Poland), M. Baranowska-Kuczko (Bialystok, Poland), I. Kasacka (Bialystok, Poland), H. Kozlowska (Bialystok, Poland)
| |